NXP800 / Nuvectis Pharma, Cancer Therapeutics CRC - LARVOL DELTA

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) - "On the NXP800 side, enrollment into the Phase 1b study in patients with platinum resistant, ARID1a mutated ovarian cancer continues, and we expect to provide an update from this study in a couple of months....We are excited about the upcoming months with NXP900 entering the Phase 1b portion of its clinical development and believe that with the recent financing we have working capital to take us through key clinical development milestones and into 2027.”"

Platinum resistant • Trial status • Endometrioid Carcinoma • Ovarian Cancer

ME09. Paul Workman: Personalized Molecular Medicine Enabled by Multidisciplinary Approaches to Cancer Drug Discovery and Clinical Development (AACR 2025) - "Examples will include the AKT inhibitor capivasertib and the developmental GCN2 activator and HSF1 pathway inhibitor NXP800. I will also describe our recent progress towards drugging the transcription factor brachyury, the primary driver of the rare bone cancer chordoma, providing an approach that can be applied to drug other oncogenic transcription factors."

Clinical • Chordoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • HSF1

Modeling response prediction to a novel GCN2 kinase activator (NXP800) in patient-derived xenograft cholangiocarcinoma models using a multi-omics approach (AACR 2025) - "Multi-omics analysis revealed a sensitivity mechanism structured around EGFR signaling, providing insights into which patients should be selected for treatment with NXP800. A Phase 1b clinical trial investigating the effects of NXP800 use in patients with advanced CCA is open and currently accepting patients."

Clinical • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • ARID1A • ATF4 • ATM • BRAF • EIF2A • EIF2S1 • FGFR1

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights (GlobeNewswire) - "NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing...NXP900 Phase 1a dose escalation study continues to enroll, preparation for the start of the Phase 1b program is underway. Phase 1b program expected to begin in mid-2025....'Enrollment is ongoing in the Phase 1b clinical trial, in which patients with platinum resistant, ARID1a-mutated ovarian cancer are currently being treated with a dose of 75mg/day, on an intermittent dosing schedule. We intend to provide an update from this study in the second quarter and plan to provide the first data from the investigator-initiated study in cholangiocarcinoma later this year.'"

Enrollment status • New P1 trial • P1 data • Cholangiocarcinoma • Ovarian Cancer

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock (GlobeNewswire) - "Nuvectis intends to use the net proceeds from the offering to continue to advance the development programs of NXP800 and NXP900 or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes."

Commercial • Oncology

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option (GlobeNewswire) - "Nuvectis intends to use the net proceeds from the offering to continue to advance the development programs of NXP800 and NXP900 or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes."

Commercial • Oncology

NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth (Clin Cancer Res) - "We demonstrate the effects of targeting the HSF1 pathway, central to cellular stress, with an inhibitor in clinical development, namely, NXP800, in prostate cancer. Targeting the HSF1 pathway with the inhibitor NXP800 decreases HSP72 expression, activates the unfolded protein response, and inhibits AR- and E2F-mediated activity, inhibiting the growth of treatment-resistant prostate cancer models."

Preclinical • Castration-Resistant Prostate Cancer

NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth. (PubMed, Clin Cancer Res) - "Overall, NXP800 has anti-tumor activity against treatment-resistant PCa models, including molecular subtypes with limited treatment options, supporting its consideration for PCa-specific clinical development."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • HSF1

New therapy hope for prostate cancer patients (PharmaTimes) - "The Institute of Cancer Research (ICR), London, found that the drug NXP800, currently in trials for ovarian and bile duct cancer, can slow prostate tumour growth and overcome hormone therapy resistance....ICR studied 439 advanced prostate cancer samples, finding higher levels of heat shock proteins linked to worse outcomes. In lab tests, NXP800 slowed growth in hormone therapy-resistant cells....Animal studies also showed promising results. In mice with resistant prostate cancers, NXP800 significantly slowed tumour growth. Without the drug, all tumours had doubled in size by 38 days; with NXP800, only 37.5% had."

Preclinical • Prostate Cancer

NXP800-101: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer (clinicaltrials.gov) - P1 | N=61 | Recruiting | Sponsor: Nuvectis Pharma, Inc. | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Metastases • Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor • ARID1A • BRCA

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer (GlobeNewswire) - P1b | N=61 | NCT05226507 | Sponsor: Nuvectis Pharma, Inc. | "Three dosing regimens have been evaluated to date in twelve patients (four patients were treated on a once per day dosing schedule, two with 75 mg/day and two with 50 mg/day. Subsequently, eight additional patients were treated with 50 mg/day on an intermittent dosing schedule of five days on / two days off, a dosing schedule implemented to mitigate thrombocytopenia)....In eleven efficacy-evaluable patients, antitumor activity was observed with best responses including one patient with an unconfirmed partial response and six patients with stable disease, including tumor shrinkage....'We expect to provide additional clinical data from the Phase 1b study in the second quarter of 2025'."

P1 data • Ovarian Cancer

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) - "'For NXP800, we anticipate the upcoming clinical data update from the Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer this month'....'For NXP900, we have cleared 4 cohorts in the dose escalation Phase 1 study so far with no reports of dose limiting toxicities, and the dose escalation continues. In parallel, we are solidifying our plans for the next stage of development with both single agent and combination approaches to unlock the full therapeutic potential of NXP900, especially in non-small cell lung cancer in combination with currently approved targeted therapies to overcome acquired resistance to such therapies'."

P1 data • Trial status • Non Small Cell Lung Cancer • Ovarian Cancer

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update (Businesswire) - "According to the recent presentations, NXP900 has shown synergy with ALK inhibitors, by strongly inhibiting ALK fusion-positive NSCLC cells that are resistant to treatment with single agent ALK inhibitors. This could extend the effectiveness of existing ALK treatments by targeting a well-established, resistance-inducing bypass mechanism....Upcoming NXP800 Data: Anticipation is growing for upcoming data from NXP800 in platinum resistant, ARID1a mutated ovarian cancer, with many watching closely to see, beyond tumor shrinking activity, if thrombocytopenia, a previously observed side effect, can be effectively managed — a major factor for the drug’s continued development."

P1 data • Preclinical • Non Small Cell Lung Cancer • Ovarian Cancer

JS03 : Emerging issues in the treatment of colon and rectal cancers (KSMO 2024) - "Additionally, Professor Paul Workman from the Institute of Cancer Research, UK, will discuss the high potential of NXP800, a drug developed to activate GCN2 as a new therapeutic target, which has received FDA Fast Track and Orphan Drug designations for ovarian and bile duct cancers. Professor Seong-Wook Lee from Dankook University will also present his work on developing innovative RNA-based therapies targeting the telomerase reverse transcriptase enzyme for challenging cancers such as brain and liver cancer. These presentations are expected to greatly enhance understanding in the field of targeted oncology therapies by focusing on drug development targeting new markers."

Biliary Cancer • Brain Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Liver Cancer • Oncology • Ovarian Cancer • Rectal Cancer • Solid Tumor • HMGB1 • TERT

Discovery and development of NXP800, a first-in-class activator of GCN2 and the Integrated Stress Response for treatment of ARID1A mutant ovarian cancer (KSMO 2024) - No abstract available

Oncology • Ovarian Cancer • Solid Tumor • ARID1A

SS03 : Oncology drug development: Translating biomarkers into breakthroughs (KSMO 2024) - "Additionally, Professor Paul Workman from the Institute of Cancer Research, UK, will discuss the high potential of NXP800, a drug developed to activate GCN2 as a new therapeutic target, which has received FDA Fast Track and Orphan Drug designations for ovarian and bile duct cancers. Professor Seong-Wook Lee from Dankook University will also present his work on developing innovative RNA-based therapies targeting the telomerase reverse transcriptase enzyme for challenging cancers such as brain and liver cancer. These presentations are expected to greatly enhance understanding in the field of targeted oncology therapies by focusing on drug development targeting new markers._x005F"

Biomarker • Biliary Cancer • Brain Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Hepatology • Liver Cancer • Oncology • Ovarian Cancer • Solid Tumor • HMGB1 • TERT

Gandouling ameliorates liver injury in Wilson's disease through the inhibition of ferroptosis by regulating the HSF1/HSPB1 pathway. (PubMed, J Cell Mol Med) - "Importantly, inhibition of this pathway by NXP800 reversed the protective effects of GDL on ferroptosis in the liver of TX mice. In conclusion, GDL shows promise in alleviating liver injury in WD by inhibiting ferroptosis through modulation of the HSF1/HSPB1 pathway, suggesting its potential as a novel therapeutic agent for treating liver ferroptosis in WD."

Journal • Genetic Disorders • Hepatology • Liver Failure • Metabolic Disorders • Movement Disorders • HSF1 • HSPB1

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers (GlobeNewswire) - "Nuvectis Pharma...announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration ('FDA') for the treatment of AT-rich interactive domain-containing protein 1a (ARID1a) ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers....Orphan Drug Designation granted by the FDA for NXP800 for the treatment of a subset of ovarian cancer, specifically for patients with an ARID1a deficiency, provides further validation for NXP800's mechanism of action and the target patient population in our ongoing Phase 1b clinical trial in patients with platinum resistant, ARID1a-mutated ovarian cancer. We expect to provide a data update from this study this coming fall."

Orphan drug • P1 data • Fallopian Tube Cancer • Ovarian Cancer • Peritoneal Cancer

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) - "For NXP800, the Phase 1b clinical trial in platinum resistant, ARID1a-mutated ovarian cancer is continuing to enroll patients at approximately 15 clinical sites in the United States and United Kingdom and we remain on track to provide an update from this study during this fall. In addition, the Investigator-sponsored clinical trial in cholangiocarcinoma is also recruiting patients, and we plan to provide an update from this trial by the end of 2024."

Trial status • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Mayo Clinic | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Mayo Clinic

Metastases • New P1 trial • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) - "We are also pleased with the recent increase in patient enrollment into the study as more clinical sites are now fully activated. In addition, our collaboration with the Mayo Clinic investigating NXP800 as a treatment option for patients with cholangiocarcinoma is also advancing, providing a second potential opportunity for NXP800 in another disease representing a severe unmet medical need."

Trial status • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Discovery of ARID1A loss as a patient biomarker for NXP800 - A developmental activator of the integrated stress response (ISR) and inhibitor of the HSF1 pathway in ovarian cancer (AACR 2024) - P1 | "We propose that ARID1A loss alters the binding and recruitment of ATF4 and HSF1 leading to the altered and prolonged expression of ATF4 target genes and increased sensitivity to NXP800. NXP800 is currently in phase Ib for the treatment of ARID1A mutant platinum resistant ovarian cancer (NCT05226507)."

Biomarker • Clinical • Oncology • Ovarian Cancer • Solid Tumor • ARID1A • ATF4 • HSF1 • SMARCA4

HSF1 inhibition induces pancreatic ductal adenocarcinoma autophagy through JNK (AACR 2024) - "Objective: The objective of this study is to investigate the molecular mechanism of HSF1 inhibition in PDAC autophagy.Methods and In human PDAC cells, Western blotting analysis revealed that HSF1 inhibition via small molecular including CCT361814/NXP800, an HSF1 inhibitor in phase I clinical trials, increased autophagy marker microtubule-associated protein 1A/1B-light chain 3 (LC3) lipidation and decreased expression of phosphorylation of HSF1 at Ser326 and total HSF1 protein, conversely using HSF1 overexpression model reversed this effect... In conclusion, JNK1/2 is involved in HSF1 inhibition-induced PDAC autophagy, targeting autophagy could unveil a novel treatment strategy for pancreatic cancer through targeted HSF1 inhibition."

Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • HSF1 • MAP1A • MAPK8

Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial (AACR 2024) - P1 | "It is envisaged that NXP800 will need to be dosed continuously and although the protocol defined MTD at 28 days at 100 mg QD, it was decided to take a dose of range of 50 mg and 75 mg OD which caused biomarker modulation, forward for further evaluation.Conclusions A tolerable dose/schedule of continuous dosing of NXP800 has been established with biomarker modulation in blood. Patients will be randomized to two dose levels 50 and 75 mg/day in a QD schedule to evaluate response in a population of ARID1A mutated, platinum-resistant, clear cell ovarian cancer (NCT05226507)."

Clinical • P1 data • PK/PD data • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Solid Tumor • ARID1A • ATF4 • TRIB3 • ULBP1